Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381756 | 0.90 | CTSA (0.51) | CTSA | |
| SCHEMBL5768896 | 0.88 | RAB9A (0.45) | CTSA | |
| SCHEMBL31444515 | 0.86 | CTSS (0.42) | CTSA | |
| SCHEMBL13306842 | 0.86 | CTSS (0.42) | CTSA | |
| SCHEMBL10216878 | 0.86 | CTSS (0.42) | CTSA | |
| SCHEMBL19744367 | 0.85 | CTSA (0.55) | CTSA | |
| SCHEMBL10217126 | 0.85 | PPARG (0.44) | CTSA | |
| SCHEMBL19744371 | 0.85 | CTSA (0.55) | CTSA | |
| SCHEMBL31757758 | 0.85 | CTSA (0.55) | CTSA | |
| SCHEMBL31444447 | 0.85 | CTSS (0.41) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101090631-A | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIV SOUTHERN CALIFORNIA (US) | 2007-12-19 | — | — | CN | claimed |
| EP-1816913-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006091246-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-31 | — | — | WO | claimed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | claimed |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-7947682-B2 | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110039714-A1 | Probes, Systems, and Methods for Drug Discovery | VTVX HOLDINGS I LLC | 2011-02-17 | — | — | US | disclosed |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| CN-101090631-A | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIV SOUTHERN CALIFORNIA (US) | 2007-12-19 | — | — | CN | disclosed |
| EP-1816913-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-10-19 | — | — | US | disclosed |
| WO-2006091246-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | disclosed |
| CN-1533400-A | Probes, system and methods for drug discovery | ����˹̩����ҩ��˾ | 2004-09-29 | — | — | CN | disclosed |
| EP-1383799-A1 | PROBES, SYSTEMS AND METHODS FOR DRUG DISCOVERY | TransTech Pharma Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003084997-A1 | PROBES, SYSTEMS AND METHODS FOR DRUG DISCOVERY | TRANSTECH PHARMA, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030125315-A1 | Probes, systems, and methods for drug discovery | TRANSTECH PHARMA, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, LIPG | CTSA 1242/4885 |
| US-20030125315-A1 | Probes, systems, and methods for drug discovery | ABCG2, EZR, PAICS | CTSA 3141/4885 |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, LIPG | CTSA 1242/4885 |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | VEGFA, TEK, MCL1 | CTSA 1116/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | CTSA 1116/4885 |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, MCL1 | CTSA 1116/4885 |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, MCL1 | CTSA 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.